"It is already known that we are facing a diabetes epidemic that will only grow worse in the next 10-20 years," said Dr. Sean Sullivan, Director of Pharmaceutical Outcomes Research and Policy at the University of Washington. "The ability to identify patients at high risk years ahead of disease diagnosis may allow us to halt diabetes progression, saving lives and helping to maintain or improve the quality of life for our patients, while also reducing the overall expenses associated with the disease."
"We are very proud to offer this innovative, clinically useful tool that enables physicians to accurately identify those at highest risk of developing Type 2 diabetes long before the disease occurs," said Mickey Urdea, founder, chairman, and CEO of Tethys Bioscience. "The PreDx Diabetes Risk Test can help physicians and patients to change the course of diabetes progression. Our mission is to provide tools that will facilitate early intervention in preventable diseases."
A presentation to be made at the ADA's 68th Scientific Sessions this
week supports the accuracy and clinical utility of the PreDx Diabetes Risk
Test. The report entitled
Training and Validation of a Multimarker Algorithm for the Prediction of
Type 2 Diabetes from a 5 Yr Prospective Study of 6,784 Danish People
J. Kolberg, et al.
shows that a simple blood test, based on multiple serum biomarkers,
indicates the risk of conversion to Type 2 diabetes, which can provide
doctors and patients with objective, quantitative information to intervene
and prevent the onset of the disease. These results are being presented in
poster format (#1019-P) from Saturday, June 7 through Monday, June 9 in
Hall D of San Francisco's Moscone Convention Center. Furthermore, a number
|SOURCE Tethys Bioscience, Inc.|
Copyright©2008 PR Newswire.
All rights reserved